CD4 and graft versus host disease: Recently, sirolimus, an mTOR inhibitor, has been clinically applied to promote the in vivo expansion of Treg cells by converting CD4+CD25− naive T cells into CD4+Foxp3+ Treg cells, thereby controlling the activity of effector T lymphocytes that cause GVHD [172].